47.69
전일 마감가:
$47.77
열려 있는:
$48
하루 거래량:
6.74M
Relative Volume:
0.42
시가총액:
$211.93B
수익:
$46.69B
순이익/손실:
$15.29B
주가수익비율:
13.89
EPS:
3.4329
순현금흐름:
$9.25B
1주 성능:
-5.07%
1개월 성능:
+0.40%
6개월 성능:
-35.50%
1년 성능:
-54.95%
노보 노디스크 Stock (NVO) Company Profile
NVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
NVO
Novo Nordisk Adr
|
47.70 | 212.27B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
LLY
Lilly Eli Co
|
1,061.40 | 932.42B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
208.84 | 506.75B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.86 | 396.44B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
135.31 | 259.09B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
101.26 | 246.17B | 63.90B | 19.05B | 13.05B | 7.5596 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-08 | 다운그레이드 | Argus | Buy → Hold |
| 2025-10-27 | 재개 | Jefferies | Underperform |
| 2025-10-01 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-09-29 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-09-16 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | 업그레이드 | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-31 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-07-30 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-04-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | 업그레이드 | Kepler | Hold → Buy |
| 2025-03-03 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-02-12 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-01-06 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Neutral |
| 2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 개시 | Argus | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
| 2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-05-04 | 개시 | Cowen | Market Perform |
| 2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss - Benzinga
Novo Nordisk (NVO) Fell Following a Profit Warning Release - Finviz
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk - Finviz
UBS Reiterates Neutral on Novo Nordisk A/S (NVO) Despite Wegovy Dose Progress - Finviz
Novo Nordisk (NVO) Hit By Lowered Guidance - Finviz
Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars - Sahm
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval - Finviz
2 Predictions for Novo Nordisk in 2026 - Finviz
Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead - ts2.tech
European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy - Sahm
Novo Nordisk (NVO) experiences muted sentiment from analysts - MSN
Novo Nordisk (NVO) Experiences Muted Sentiment From Analysts - Finviz
Why Novo Nordisk Stock Topped the Market on Thursday - Finviz
Novo Nordisk (NVO) Partners With Indian Health-Tech Startup - Finviz
Argus Downgrades Novo Nordisk A/S (NVO) to Hold From Buy - Finviz
Analysts See Upside In Novo Nordisk A/S (NVO) Driven By Diabetes And Obesity Trends - Finviz
Why Novo Nordisk Stock Was Melting on Monday - Finviz
Novo Nordisk A/S (NVO): A Bull Case Theory - Finviz
Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know. - Finviz
Why Novo Nordisk Stock Just Hit a 4-Year Low - Finviz
European Drugmakers And Banks Put ADRs In The Green - Finimize
Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029 - Finviz
J.P. Morgan Reiterates a Buy Rating on Novo Nordisk (NVO) - Finviz
Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B - TradingView
NVONovo Nordisk ADR Earnings - Finviz
Novo Nordisk Wants FDA Nod For A Higher-Dose Wegovy - Sahm
Medicare Announces Price Cuts For 15 Drugs— Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month - Sahm
Did Pfizer Just Say "Checkmate" to Novo Nordisk? - Finviz
Novo Nordisk Alzheimer's Miss Disappointing But Not Material, Analyst Says - Sahm
European ADRs Stay Put As Novo Nordisk Slides - Finimize
Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes Patients - Sahm
Novo Nordisk (NVO) is Trending On RedditHere's Why - Finviz
Novo Nordisk's Wegovy Shows Weight Loss-Independent Liver Benefits in MASH Trial Data - Finviz
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):